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CDC42 interacting protein 4 (CIP4) is a CDC42 effector that coordinates membrane deformation 
and actin polymerization. The correlation of CIP4 overexpression with metastatic capacity has 
been characterized in several types of cancer. However, little information exists on how CIP4 
function is regulated. CIP4 interacts with A-kinase (PKA) anchoring protein 350 (AKAP350) 
and CIP4 is also a PKA substrate. Here, we identifid CIP4 T225 as the major CIP4 PKA 
phosphorylation site. In vitro and in vivo experiments using hepatocellular carcinoma (HCC) and 
breast cancer cells showed that expression of a CIP4(T225E) phosphomimetic mutant increased 
cancer cell metastatic capacity and that, conversely, expression of a CIP4(T225A) non-
phosphorylatable mutant reduced invasive properties. PKA inhibition decreased to CIP4(T225A) 
cell-levels control but not CIP4(T225E) cell migratory and invasive efficiency. Concomitantly, 
our studies indicate that CIP4 T225 phosphorylation promotes the formation of functional 
invadopodia and enhances CIP4 localization at these structures. Our findings further provide 
mechanistic data indicating that CIP4 T225 phosphorylation facilitates CIP4 interaction with 
CDC42. Altogether this study identifies a signaling pathway that involves CIP4 phosphorylation 
by PKA during the acquisition of a metastatic phenotype in cancer cells. 
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CIP4 (TRIP10) is an adaptor protein initially identified by its interaction with the activated form 
of CDC42 [1]. Structurally, CIP4 belongs to the family of F-BAR proteins. These F-BAR 
proteins contain an amino-terminal Fes-CIP4 homology domain followed by a coiled-coil region 
(F-BAR or extended FER CIP4 homology (EFC) domain), which interacts with negatively 
charged membrane phospholipids promoting membrane curvature [2]. CIP4 also contains a Src 
Homology 3 (SH3) domain at the carboxyl terminus that mediates its interaction with the 
proline-rich domains of WASP and its related proteins WAVE and N-WASP, which are 
activators of  the Arp2/3 complex and promote local formation of branched actin filaments [3,4]. 
By means of its SH3 domain, CIP4 also interacts with formins Dia and DAAM1, which generate 
nucleation of linear actin filaments, and with dynamin-2 [3,5,6]. Hence, CIP4 coordinates 
membrane deformation with vesicle scission and actin polymerization, participating in processes 
that involve generation of membrane protrusions, endocytosis and vesicle movement [4].  
     Other studies have demonstrated that CIP4 overexpression correlates with cell invasiveness 
and metastatic capacity in osteosarcoma, breast cancer, non-small lung and nasopharyngeal 
cancer cells [7-12]. Our own investigations have shown that CIP4 participates in the acquisition 
of migratory properties in HCC cells [13]. The pro-metastatic role of CIP4 has been particularly 
well characterized in breast cancer. In MDA-MB-231 triple negative breast cancer cells, CIP4 is 
fundamental for invadopodia formation and, therefor, for cell invasiveness in response to EGFR 
activation [7].  Furthermore, Rolland and colleagues demonstrated that, in normal breast 
epithelial cells, CIP4 promotes E-cadherin endocytosis and disruption of cellular junctions, 
which are the initial events in the acquisition of a migratory phenotype [8]. That study also 
showed that CIP4 levels are significantly increased in clinically aggressive breast cancers and 
















with disease relapse. Similar results were obtained by an independent study, which also 
identified CIP4 as a potential biomarker for poor prognosis in human breast cancer patients [11].  
     Even though most of the evidence collected in normal epithelia and cancer cells positions 
CIP4 as a prometastatic protein, studies performed in fibroblast-derived cells and in breast 
cancer cells that overexpress Src kinase showed that CIP4 can negatively regulate cell migration 
and invadopodia function [14,15]. Those results suggest that the pro-invasive effects of CIP4 are 
cellular context-dependent. CIP4 interacts with the A-kinase anchoring protein AKAP350 (also 
known as AKAP450 or AKAP9) by means of its F-BAR domain [16]. In this scenario, 
AKAP350, which itself  regulates metastatic features in several cancer cells [13,17-19], 
represents a likely candidate to regulate CIP4 functio . In fact, our recent studies indicate that, in 
HCC cells, CIP4 interaction with AKAP350 is importan  for the acquisition of the migratory 
phenotype that enables directional cell migration [13]. CIP4 is an endogenous PKA substrate 
[16]. The role for PKA in tumor cell acquisition ofinvasive properties is complex, since it is 
dependent on the substrates that PKA phosphorylates in each specific condition [20]. In the 
present study, we evaluated the effect of CIP4 phosrylation by PKA on the modulation of the 
invasive properties of HCC and breast cancer cells and characterized the mechanisms involved in 
this activity. 
2. Materials and methods 
2.1. Cell culture 
 MDCK cells were obtained from Keith Mostov lab (UCSF, CA). HepG2/C3a and MDA-MB-
231 cells were purchased from the American Type Culture Collection. Cells were grown on 
plastic flasks in Dulbecco’s modified Eagle’s medium with 4.5 gm of glucose/L, supplemented 
with 10% fetal bovine serum and antibiotics. Cells were tested monthly by PCR for 
















2.2. Relevance of AKAP350 expression on CIP4 phosphorylation in situ 
 Cells with decreased AKAP350 expression were prepared using a lentiviral system to express 
two different AKAP350 specific short hairpin RNAs (hRNA1 and shRNA4) as described [13]. 
Silencing was confirmed by western blotting and immunofluorescence analyses, using mouse 
monoclonal anti-AKAP350 (14G2) antibody [13,21]. CIP4 immunoprecipitation and 
identification of its phosphorylation in RXXS/T residues was performed using Phospho-PKA 
substrate antibody (Cell Signalling), as described in the supplementary material.  
2.3. Identification of CIP4 PKA phosphorylation site 
  In silico identification of putative PKA substrate sites in CIP4 sequence was performed using 
three phosphorylation sites prediction servers: Expassy bioinformatics portal 
(http://www.cbs.dtu.dk/services/NetPhosK/) [22], Group-based phosphorylation scoring method 
(http://www.phospho.elm.eu.org) and Prediction of PK-specific Phosphorylation site 
(http://www.ppsp.biocuckoo.org) [23]. Mutants of the putative phosphorylation sites were 
prepared using a Quickchange method with complementary mutated primer sequences and a full 
length CIP4 cDNA cloned into the pET30c vector [15] as template to amplify CIP4 sequence by 
PCR. The recombinant proteins were produced using BL21(DE3)pLysS bacteria and purified 
using Ni-beads and CIP4 in vitro phosphorylation was assessed as described in Supplementary 
methods.  
2.4. Generation of CIP4 wild type (CIP4 WT), CIP4(T225A) and CIP4(T225E) cell lines 
 Plasmids for expression of CIP4T225 mutants in HepG2 cells were generated by using 
Quickchange complementary mutated primers and pEGFP-CIP4 plasmid [13] as template to 
amplify CIP4 sequence by PCR. The pEGFP plasmids containing CIP4 WT, CIP4(T225A) or 
CIP4(T225E) sequences were used as templates to clone each of the CIP4 sequences into the 
















CIP4(T225A) or CIP4(T225E) cells. Detailed information about those procedures and cell 
transfection and selection are available in the Supplementary methods section. 
2.5. Evaluation of CIP4 T225 phosphorylation at cellular level 
  MDA-MB-231 CIP4WT and CIP4T225A cells were incubated with 10 µM Forskolin 
(Sigma) for 10 min. After incubation, cells were scraped into cold PBS containing protease and 
phosphatase inhibitors (Sigma-Aldrich). Cells were lysed and immunoprecipitates were prepared 
by using mouse anti-GFP antibody (abcam, #ab290) and analyzed by western blot by using an 
antibody that recognizes the phosphorylated RXXS/T site or anti-GFP as described in the 
Supplementary methods section. 
2.6. Wound healing and in vitro invasion assays  
 HepG2 or MDA-MB-231 cells seeded at 2.5×106 cells in 2 ml of DMEM were cultured 
overnight at 37°C in 6-well plates. Cell cultures were wounded by dragging a 100 µl pipette tip 
through the monolayer, washed using PBS to remove cellular debris and allowed to migrate. For 
MDA-MB-231 experiments, images of wounds in the same field were captured when the wound 
was introduced (0 h) and 6 h after wounding using a inverted microscope. Wound closure was 
assessed using ImageJ software. For HepG2 experiments, c lls were fixed at 6 h or 24 h after the 
wound was performed, immunostained and analyzed by confocal microscopy as described in the 
Supplementary methods. The front-rear migratory polarity was evaluated at 6 h by measuring the 
distance from the nucleus, the centrosome or the cell centroid to the wound edge, and calculating 
the distance from the nucleus and the centrosome to the cell centroid, as we have previously 
described [13]. In vitro cell invasion assays were performed in 10 mm diameter and 8 µm pore 
polycarbonate filter Transwell plates. Membranes were pre-coated with 20 µg of matrigel, which 
formed a reconstituted basement membrane at 37°C. Suspensions of 1 × 105 HepG2 or 5 × 104 
MDA-MB-231 cells in serum-free DMEM were added to the upper chamber, and the lower 
















or 24 h for MDA-MB-231 cells, cells that had invaded the lower chamber were fixed with 
methanol, stained with 1% Toluidine Blue in 1% borax for 5 min, and counted using an inverted 
microscope. 
2.7. Animal studies  
 Experiments were performed using 6 week-old female athymic nude mice (6 per group), 
obtained from the School of Veterinary Sciences at the National University of La Plata. During 
the experiments, the animals were treated in accordance with the Canadian Council on Animal 
Care guidelines. To analyze the effect of CIP4 T225 mutants on the ability of HCC cells to 
invade and colonize the lungs, HepG2 cells were suspended in PBS (2 × 107 cells per ml). One 
hundred µl of the suspension was injected into the mouse lateral ail vein (experimental 
metastasis studies). In order to analyze the effect of CIP4 T225 mutants on the tumorigenic and 
metastatic properties of breast cancer cells, MDA-MB 231 cells were suspended (2 × 107 cell per 
ml) in an ice-cold 50:50 solution of Matrigel and PBS. Fifty µl of the final cell suspension was 
introduced into the right inguinal mammary gland of anaesthetized mice using a 25-gauge 
needle. Primary tumor growth was analyzed by measuring tumor length (a) and width (b) with a 
caliper every 3-4 days, and tumor volume (V) was calcul ted using the formula V = 0.4ab2. After 
8 weeks in experimental metastasis, or 12 weeks in spo taneous metastasis experiments, mice 
were euthanized, the chest cavity was exposed throug  a midline chest incision, the trachea 
cannulated with a 20-gauge needle and lungs slowly inflated using 1 ml of India ink (1:16 in 
PBS). Lungs were extracted, immersed in Fekete's solution and metastatic nodules were counted 
visually. Lungs were embedded in paraffin and cut into 4 µm sections and stained with 
hematoxylin and eosin. Additionally, lung sections were analyzed by immunohistochemistry 
using an anti-pan-cytokeratin antibody (Santa Cruz-8018, C-11, 1:50) developed with a 
Vectastain ABC Kit (Vector laboratories). 
















 We evaluated the formation of functional invadopodia as previously described (24). Briefly, 
cells were plated on coverslips coated with gelatin co jugated to FITC (Thermo Fisher 
Scientific: G13187) in 6-well plates at 4 x104 cells/ml, incubated 16 h at 37ºC and then fixed an 
stained with phalloidin-Alexa 555 and rabbit anti-cortactin-antibody (GTX100253). Images were 
obtained using a Nikon C2+ confocal system mounted on a Nikon TiE inverted microscope. Foci 
of degraded matrix were visible as dark areas of 0.2 to 1.2 µm in diameter in the bright 
fluorescent gelatin matrix. A cell generating at least one “hole” under the cell or near the cell 
edge was counted as a cell able to degrade extracellul r matrix (ECM). Functional invadopodia 
were identified as actin- and cortactin-rich membrane structures localized close to sites of 
degraded ECM. To assess localization of CIP4 mutants t invadopodia, cells were grown on 
Matrigel–coated dishes at 4 x104/ml in complete medium, allowed to invade for 16 h, and 
invadopodia were identified as previously described [14]. Invadopodia were counted from 6 to 
10 random fields in each sample and averaged over thr e independent experiments.  
2.9. Imaging Förster resonance energy transfer (FRET) measurements 
 In the present study, the acceptor bleaching FRET method was used, as previously described 
in detail [25] using an LSM880 confocal with an ObserverZ1 inverted microscope. GFP-CIP4 
chimeric proteins were used as donor fluorophores, and mouse monoclonal anti-CDC42 antibody 
detected with secondary antibody labeled with Alexa 555 as acceptor fluorophore. The acceptor 
dye was photobleached using the 555 laser line (100% power, 70 iterations of 130 ms) at the 
membrane region. The energy transfer was detected as an increase in donor fluorescence 
(dequenching) after photobleaching the acceptor flurophore. FRET efficiency was calculated 
as: (IDa-IDb)/IDa, IDa and IDb being the fluorescen intensity of the donor channel at the 
quenched area after and before the photobleaching, respectively. As a negative control, we used 
















Alexa 555. Additionally, FRET efficiency was calculated in areas of the same fields that were 
not subjected to photobleaching.  
2.10. Statistical analysis 
 Data are expressed as the mean ± s.e.m. and are representative of at least three experiments. 
Paired Student’s t-test was used for comparisons between experiments or for comparisons within 
each experiment when mixed populations of cells were used. Otherwise, non-parametric Mann–
Whitney test was used for comparisons within each experiment. p<0.05 was considered 
statistically significant. 
3. Results  
3.1. AKAP350 regulates CIP4 phosphorylation by PKA  
 To evaluate AKAP350 participation in CIP4 phosphorylation by PKA, we generated 
AKAP350 knocked down (AKAP350KD) cells by using a lentiviral system to express two 
different AKAP350 specific short hairpin RNAs (shRNA1 and shRNA4) (Supplementary Fig. 
1A). The analysis of AKAP350 protein levels showed that, whereas the expression of both 
shRNAs efficiently decreased AKAP350 levels, shRNA1 was more effective than shRNA4 
(shRNA1:-75%; shRNA4:-55%). Control and AKAP350KD cells were incubated in conditions 
of PKA activation, and the phosphorylation on CIP4 RXXS/T PKA consensus motifs was 
analyzed in CIP4 cell lysate immunoprecipitates by western blot. Our results showed that CIP4 
phosphorylation by PKA was severely impaired both in shRNA1 and shRNA4 AKAP350KD 
cells (Supplementary Fig. 1B). The analysis of three independent experiments performed with 
shRNA1 AKAP350 KD cells indicated a mean 70% decrease in PKA phosphorylated-CIP4 
levels (Fig. 1). These results indicated that AKAP350 facilitates CIP4 phosphorylation by PKA. 
















 CIP4 interacts with the plasma membrane by means of it amino-terminal F-BAR domain, 
whereas its interaction with cdc42 and WASP is mediat  by its HR1 and SH3 domains, 
respectively (Fig. 2A). To identify the specific site n the CIP4 sequence that is phosphorylated 
by PKA, we initially performed an in silico analysis using three different phosphorylation site 
prediction servers (see Materials and methods). The analysis revealed the presence of four 
putative PKA phosphorylation sites in the CIP4 sequence: T225, S296, S421 and S426. To 
determine which of these sites was actually phosphorylated, we generated expression plasmids 
for four CIP4 mutant versions where each amino acidwas replaced by alanine, and  performed in 
vitro phosphorylation assays using the recombinant proteins. Our results showed that, when 
exposed to the PKA catalytic subunit, phosphorylation levels of CIP4(S296A), CIP4(S421A) and 
CIP4(S426A) mutants were similar to those of the wild-type protein (data not shown). Moreover, 
the triple mutant (S296, S421A, S426A) exhibited normal phosphorylation levels (Fig. 2B). In 
contrast, phosphorylation by PKA was completely absent in the CIP4(T225A) mutant (Fig. 2B), 
thus revealing this exclusive PKA phosphorylation site located within the CIP4 F-BAR domain. 
The in silico analysis of CIP4 quaternary structure, based on  the resolution of the F-BAR 
domain crystal structure (https://www.ncbi.nlm.nih.gov/Structure/pdb/2EFK), revealed that T225 
is positioned at the convex side of the F-BAR domain (F g. 2C). Remarkably, we found that the 
T225 residue is highly conserved in mammals, althoug  it is absent in zebrafish and other non-
placental chordates and it is missing in the other CIP4-like proteins (formin-binding protein 
(FBP) 17 and transducer of CDC42-dependent actin assembly (TOCA) 1) (Fig. 2D).  To evaluate 
if the CIP4 T225 residue is also a relevant PKA phosphorylation site at cellular level, we 
generated MDA-MB-231 cells with stable overexpression of CIP4 (CIP4WT) or CIP4(T225A) 
non-phosphorylatable mutant by transducing cells with pseudo-retroviral particles containing the 
constructs that code for their respective GFP fusion pr teins. The expression of CIP4 chimeric 
proteins and the maintenance of endogenous CIP4 levels in the different cells were verified by 
















fusion proteins on RXXS/T sites was analyzed in conditions of PKA stimulation (Fig. 2E). 
Immunoprecipitates were prepared using an anti-GFP primary antibody, and RXXS/T 
phosphorylation was analyzed using anti-RXXS/T-Pi specific antibody, as described in Fig. 1. 
Our results showed that CIP4 WT was significantly immunoreactive, whereas the CIP4T225A 
mutant showed negligible immunoreactivity with the RXXS/T-Pi specific antibody. Considering 
our in vitro results, this low immunoreactive signal could be either a non-specific signal, or a 
different RXXS/T phosphorylation site that was phosphorylated less efficiently. These studies 
give strong support to the idea that CIP4 T225 is, at least, the prevalent CIP4  PKA 
phosphorylation site in situ. 
3.3. Expression of a CIP4(T225E) phosphomimetic mutant increases the migratory efficiency in 
HepG2 cells  
 HepG2 are HCC-derived cells, which retain many of the epithelial characteristics of 
hepatocytes. Concomitantly, HepG2 cells are poorly invasive. Our previous studies showed that, 
when subjected to wound healing assays, the acquisition of a migratory phenotype in HepG2 
cells depends on both CIP4 and AKAP350 expression [13]. Therefore, we evaluated the 
relevance of CIP4 phosphorylation by PKA to the acquisition of migratory and invasive 
properties in HepG2 cells. We prepared HepG2 cells with stable expression of CIP4 (CIP4WT), 
the CIP4(T225E) phosphomimetic or the CIP4(T225A) non-phosphorylatable mutants as GFP 
fusion proteins. The analysis of CIP4 fusion proteins expression by western blot showed that 
protein levels did not differ significantly among mutants (Supplementary Fig. 3). Considering 
the low migratory efficiency of HepG2 cells, we performed experimental wound healing assays 
using a mixed population of cells that contained equal numbers of CIP4(T225E) or CIP4(T225A) 
and control cells. After 24 h, we calculated the ratio for each group of cells at the wound edge 
(Fig. 3A) and compared it to the ratio of cells that were located in the monolayer, far from the 
wound edge. As compared to traditional wound healing assays, this method allows higher 
















originating in differences in cell proliferation rates [13]. Our results showed that, compared to 
control cells, the migratory efficiency was doubled in CIP4(T225E), and reduced to 25% in 
CIP4(T225A) cells (Fig. 3 B), demonstrating an eight-fold increase in the migratory efficiency 
for cells expressing the phosphomimetic mutant with respect to the cells expressing the non-
phosphorylatable mutant. On the other hand, we did not observe any difference in directional cell 
migration efficiency between control and CIP4WT cells. Directional cell migration requires the 
asymmetric reorganization of the cell components in order to acquire a front–rear polarity, which 
ensures the directional trafficking of membranes and regulatory proteins towards the leading 
edge. The acquisition of this migratory polarity involves nucleus movement to the back and 
centrosomal relocation to the front of the nucleus [26]. Concurrently, the analysis of centrosome 
position relative to the nucleus in HepG2 cells showed that the acquisition of a migratory 
phenotype was impaired by the expression of CIP4(T225A) (Fig. 3C). An initial event in the 
acquisition of the migratory phenotype in epithelial cells is the disruption of adherens junctions 
by E-cadherin endocytosis and degradation. Considering that E-cadherin endocytosis can be 
regulated by CIP4, E-cadherin protein levels in the different cell populations were analyzed by 
western blot. In accordance with the wound healing results, E-cadherin levels were significantly 
decreased in CIP4(T225E) cells, but were unaffected in CIP4(T225A) cells (Fig. 3D). In 
CIP4WT-expressing cells, there was a subtle decrease in E-cadherin levels that was not 
statistically significant. This is consistent with previous studies from other authors, who showed 
that, whereas CIP4 overexpression is associated with E-cadherin endocytosis, total levels of E-
cadherin were not affected by changes in CIP4 expression [8]. Taking everything into account, 
these results indicate that  CIP4 T225 phosphorylation is a regulatory event relevant to the 
acquisition of the mesenchymal, migratory phenotype in HepG2 cells. 
      Our recent studies have demonstrated that PKAinhibition decreased HepG2 migratory 
efficiency in wound healing assays (27). We performed wound healing assays in mixed 
















PKA inhibitor, H89 (Fig. 3E). PKA inhibition eliminated the differences in migratory efficiency 
between control and CIP4(T225A) cells and, conversely, potentiated the migratory advantage 
conferred by the expression of the CIP4(T225E) mutant. These results highlight the significance 
of CIP4 T225 phosphorylation for PKA regulatory effect on HepG2 cell migration. 
3.4. Expression of the CIP4(T225E) phosphomimetic mutant enhances HepG2 cell invasiveness 
 We further analyzed the relevance of CIP4 T225 phos rylation to HepG2 cell invasiveness 
using in vitro and in vivo assays. Our in vitro experiments performed in Matrigel-coated 
permeable transwells showed that expression of the CIP4(T225E) mutant markedly increased the 
number of cells invading the lower chamber (+1100%), as opposed to the expression of the 
CIP4(T225A) mutant, which severely impaired cell invasiveness (-90%) (Fig. 4A). Likewise, 
experimental metastasis experiments performed by inject g control, CIP4 WT, CIP4(T225E) or 
CIP4(T225A) HepG2 cells into the tail vein of athymic nude mice, showed that, compared to 
CIP4 WT cells, CIP4(T225E) cells were much more efficient, whereas CIP4(T225A) cells were 
significantly less efficient in generating metastatic nodules (Fig. 4B,C).  The analysis of the 
hematoxylin and eosin staining of the lungs (Fig. 4D) and the immunohistochemical staining for 
cytokeratins in lung proximal lymphatic nodes (Supplementary Fig. 4) were consistent with these 
observations. Overall, these results indicate that CIP4 T225 phosphorylation is a central event in 
the regulation of HCC cell metastatic properties. 
3.5. CIP4 T225 phosphorylation participates in the acquisition of MDA-MB-231 cell migratory 
and invasive properties 
 MDA-MB-231 cells are triple negative breast cancer lls, whose highly metastatic properties 
rely, at least partially, on their elevated CIP4 levels [7]. Hence, we analyzed the relevance of 
CIP4 T225 phosphorylation to MDA-MB-231 cell acquisition of migratory and invasive 
properties. MDA-MB-231 cells with stable expression of CIP4WT, CIP4(T225A) and 
















these cell lines showed that CIP4(T225A) expression g ificantly inhibited, whereas 
CIP4(T225E) expression significantly increased, the efficiency of directional cell migration in 
MDA-MB-231 cells (Fig. 5A), indicating that the pres nce of the phosphomimetic residue in this 
position gave a migratory advantage to these cells.  
 Previous studies demonstrated that the activation of PKA increases MDA-MB-231 cell 
invasiveness [28]. We analyzed the effect of the expr ssion of CIP4 T225 mutants on cell 
invasiveness in basal conditions and in the presence of the PKA inhibitory peptide, PKI. In vitro 
invasion assays showed that CIP4(T225A) cells were less invasive whereas CIP4(T225E) cells 
were significantly more invasive than control or CIP4 WT-expressing cells (Fig. 5B). The 
presence of the PKA inhibitor (PKI) decreased control and CIP4 WT cell invasiveness to 
CIP4(T225A) levels, without modifying CIP4(T225A) cell invasiveness. On the other hand, 
although CIP4(T225E) cell invasiveness was inhibited n the presence of PKI, it still remained 
significantly higher than control or CIP4 WT cells in the same conditions. These results reveal 
that CIP4 T225 is a significant PKA substrate in the pathway regulating cell invasiveness in 
triple negative breast cancer cells.  
3.6. Expression of the CIP4(T225E) phosphomimetic mutant promotes spontaneous metastasis in 
MDA-MB-231 orthotopic xenografts in athymic nude mice 
 To test whether CIP4 T225 phosphorylation regulates tumor progression and metastasis, 
MDA-MB-231 cells were orthotopically injected into he mammary fat pad of athymic nude 
mice. Overexpression of CIP4 WT or expression of CIP4(T225A) or CIP4(T225E) mutants did 
not affect tumor growth (Fig. 6A,B). On the other hand, CIP4 overexpression enhanced 
spontaneous metastasis (Fig. 6C). Furthermore, we obs rved that mice injected with cells 
expressing the CIP4(T225E) phosphomimetic mutant developed lung nodules at an even higher 
frequency, considering both the number of mice that developed metastasis (Fig. 6C) and the 
















with CIP4(T225A) cells rarely developed lung metastasis (Fig. 6C-D). The analysis of the 
hematoxylin and eosin staining of the lungs supported these observations (Fig. 6E). Similarly, 
the analysis of the immunohistochemical staining for cytokeratins in lung proximal lymphatic 
nodules revealed the presence of an increased number of cytokeratin positive cells in mice 
injected with CIP4(T225E) cells when compared to mice injected with CIP4 WT or 
CIP4(T225A) cells (Supplementary Fig. 5). 
3.7. Expression of the CIP4 T225 non-phosphorylatabe mutant decreases CIP4 interaction with 
CDC42 at the cell edge and inhibits invadopodia formation 
 CIP4 enhancement of triple negative breast cancer cell invasiveness is, at least in part, due to 
its role in invadopodia formation. We analyzed the formation of functional invadopodia in 
MDA-MB-231 CIP4 WT, CIP4(T225A) and CIP4(T225E) cells grown on coverslips coated with 
FITC-conjugated gelatin. Functional invadopodia were identified as actin/cortatctin positive 
structures in contact with the ECM that were able to degrade gelatin. Our results showed that 
expression of CIP4(T225A) inhibited, whereas expression of CIP4(T225E) slightly increased the 
generation of functional invadopodia (Fig. 7A-C).We further analyzed the subcellular 
localization of the CIP4 T225 mutants. Invadopodia visualization in the orthogonal views of the 
image stacks showed that, as previously described, CIP4 was enriched at such structures [7]. 
Compared to CIP4 WT, CIP4(T225E) levels at invadopodia were significantly higher, whereas 
CIP4(T225A) localization at these structures was not so prominent (Fig. 7D).  
 Considering that the role of CIP4 in invadopodia formation is dependent on its interaction 
with CDC42, we analyzed if CIP4 T225 phosphorylation was relevant for this interaction. We 
analyzed the in situ CIP4/CDC42 interaction at the cell edge in MDA-MB-231 CIP4 WT and 
CIP4(T225A) cells using immuno FRET by acceptor photobleaching. Cells that expressed GFP 
alone were used as negative controls. Our results showed that, even when both CIP4 WT and 
















efficiency (-43%, p<0.05), indicating that CIP4/CDC42 interaction was inhibited by the presence 
of a non-phosphorylatable amino acid in the T225 position (Fig. 7E). We did not observe any 
significant difference in FRET efficiency between CIP4(T225E)/CDC42 and 
CIP4(T225WT)/CDC42 donor/acceptor pairs (data not sh wn). 
4. Discussion 
 During disease progression, cancer cells are exposd t  conditions that impose severe 
limitations on proliferation and survival. Therefore, the capacity to dynamically regulate cell 
behavior  gives cells an important advantage, particularly during metastatic spread. 
Phosphorylation is a common reversible mechanism for triggering or inhibiting the activity of 
specific proteins in a signaling pathway. Hence, it is not surprising that altered phosphorylation 
of key proteins participates in oncogenic mechanisms. Specifically, PKA plays a regulatory role 
in cancer initiation and progression by either enhancing or inhibiting proliferation and 
dissemination of malignant cells in a cancer-dependent manner [20,29]. PKA is a 
serine/threonine kinase whose interaction with its scaffolding proteins by means of its regulatory 
domain determines its accessibility to specific substrates [30]. In this regard, the traditional 
model proposes that, upon cAMP interaction with the regulatory subunit, PKA catalytic subunits 
are activated and released from the complex. Neverthel ss, recent studies have proposed that 
increases in cAMP within physiological levels activa e PKA without inducing the separation of 
the catalytic subunit [31]. Therefore, protein phosphorylation is much more regionally confined 
than previously appreciated and it is restricted to substrates within the immediate vicinity of 
PKA scaffolded by particular AKAPs. Accordingly, recent studies have demonstrated that 
interference with the interaction between PKA and its anchoring proteins impairs PKA-mediated 
tumorigenesis in mammary epithelial cells [32,33].  CIP4 is a PKA substrate which interacts 
with the PKA anchoring protein AKAP350 [16]. In the present study, we found that CIP4 
















the exclusive CIP4 PKA phosphorylation site. Considering that different lines of evidence 
suggest a functional interaction between CIP4 and AKAP350 during the acquisition of invasive 
properties [13,19], we hypothesized that CIP4 T225 phosphorylation by PKA regulates CIP4 
function during the development of invasive properties in cancer cells. 
 In spite of its pro-invasive effects in breast cancer, osteosarcoma, nasopharyngeal and small 
lung cancer cells, CIP4 overexpression leads to decreased cell migration and invasion in NIH 
3T3 fibroblastic cells [15]. Moreover, in vitro experiments performed in MDA-MB-231 cells 
showed that CIP4 Y471 phosphorylation by Src could induce an anti-invasive effect of CIP4 
[14]. In the present study, we provide evidence that CIP4 phosphorylation at CIP4 T225 by PKA 
enhances its pro-invasive activity both in HCC and in triple negative breast cancer cells: First, in 
HepG2 cells, expression of the CIP4(T225E) phosphomimetic mutant decreased E-cadherin 
protein levels, whereas expression of the CIP4(T225A) non-phosphorylatable mutant inhibited 
the acquisition of a migratory phenotype.  Second, expression of CIP4(T225E) increased, 
whereas expression of CIP4(T225A) decreased the migratory efficiency and invasiveness in 
HepG2 and MDA-MB-231 cells. Concomitantly, CIP4(T225A) expression inhibited the capacity 
of MDA-MB-231 cells to develop functional invadopodia. Third, experiments in athymic mice 
showed that HepG2 and MDA-MB-231 cells expressing the phosphomimetic mutant were more 
prone to develop lung metastases.  Fourth, the promig atory and proinvasive effects of PKA in 
HepG2 and MDA-MB-231 cells were prevented by the prsence of the CIP4(T225A) non-
phosphorylatable mutant, which indicates that CIP4 constitutes an important substrate in the 
signaling pathways involving PKA as a tumor-promoting kinase.  
 CIP4 participation in cell acquisition of migratory and invasive properties is linked to its role 
as a CDC42 effector in coordinating actin cytoskeleton remodeling and membrane deformation. 
Those processes are essential for E-cadherin endocytosis as well as for the formation of 
















role of CIP4 in membrane deformation is reliant on the direct interaction of its F-BAR domain 
with the membrane [2], whereas its participation in actin nucleation depends on its simultaneous 
interaction with active CDC42 and N-WASP [1,3,4].  N-WASP interaction with active CDC42 is 
essential for the generation of its “open” conformation, which promotes actin nucleation [35,36]. 
In this scenario, by directly interacting with N-WASP and active CDC42, CIP4 acts as a 
membrane bound scaffold that facilitates N-WASP activ tion [7]. CIP4 interacts with active 
CDC42 by means of its HR1 domain, located C-terminal to the F-BAR domain (Fig. 1A) [1].  
FRET analysis of MB-231 CIP4 WT and CIP4(T225A) cells showed that mutation of CIP4 T225 
to the non-phosphorylatable amino acid alanine inhibited CIP4 interaction with CDC42 at the 
cell edge. Thus, CIP4 interaction with CDC42 was dependent on CIP4 T225 phosphorylation. 
We have not been able to verify these in situ findings by biochemical assays, because we could 
not co-immunoprecipitate endogenous CDC42 with CIP4. This is most likely related to the fact 
that CIP4 HR1 domain (as well as FBP17 and TOCA-1 HR1 domains) has a remarkably low 
affinity for CDC42. In vivo, this makes their interaction dependent on the compart entalization 
of both proteins at the membrane, which is lost under  immunoprecipitation conditions [37]. 
Therefore, CIP4 phosphorylation could favor cell migration and invasion by increasing its 
interaction with active CDC42 at the membrane, hence regulating actin nucleation at membrane 
protrusions. In accordance with our hypothesis, we found that expression of the CIP4(T225A) 
mutant inhibited invadopodia formation. In addition, CIP4 localization at invadopodia was 
enhanced by the presence of the phosphomimetic mutation, but was decreased by the presence of 
the non-phosphorylatable mutant. At this point, a relevant question is: How does CIP4 T225 
phosphorylation regulate the protein localization t invadopodia? CIP4 T225 is positioned at the 
convex side of F-BAR domain, whereas its concave surface is the one responsible for CIP4 
interaction with the plasma membrane [38]. Therefore, it is not likely that T225 phosphorylation 
directly affects CIP4 interaction with plasma membrane phospholipids. Previous studies 
















We might speculate that decreased localization of CIP4 to invadopodia could be related to its 
decreased interaction with CDC42. Nevertheless, studies performed in cortical neurons showed 
that the CIP4 HR1 domain barely affected CIP4 localization to protruding membranes, indicating 
that direct interaction with CDC42 was dispensable for CIP4 localization at those structures [39]. 
Instead, the decrease in CIP4 interaction with CDC42 could be the consequence of its decreased 
ability to localize to invadopodia. The F-BAR domain is also responsible for CIP4 dimerization. 
Considering that CIP4 interaction with the plasma membrane is dependent on its dimerization, 
future studies will focus on elucidating if CIP4 T225 phosphorylation has a direct impact on 
CIP4 dimerization and interaction with the plasma membrane and/or on its ability to directly 
interact with CDC42. 
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Fig. 1. Western blot analysis of CIP4 phosphorylation in cotr l and AKAP350KD cells. (A) 
Cell lysates from MDCK cells transduced with shRNA1 ( KAP350KD) or scrambled shRNA1 
(control) expressing lentiviral particles were resolved on 6% SDS-polyacrylamide gel 
electrophoresis, transferred to nitrocellulose membranes and analyzed by western blot using 
mouse monoclonal anti-AKAP350 (14G2, 1:500) and anti-α-tubulin (Sigma-T9026, 1:3000) 
antibodies. (B) Control and AKAP350KD MDCK cells were incubated in the presence of 10 µm
forskolin (Sigma) for 10 min, and lysed in the presence of phosphatase inhibitors. CIP4 
immunoprecipitates were obtained from control and AKAP350KD cells using a mouse anti-CIP4 
antibody and phosphorylation by PKA in the immunoprecipitates was analyzed by western blot 
using an antibody that recognizes the RXXS/T(Pi) consensus motif (Supplementary methods). 
Bars indicate mean levels of RXXS/T(Pi) positive CIP4 levels, related to total CIP4 levels, 
expressed as percentage of controls of three indepent experiments.  
Fig. 2. PKA phosphorylates the CIP4 T225 residue, located in the CIP4 F-BAR domain. (A) 
Cartoon delineating CIP4 domains: F-BAR domain (CIP4 5-257), responsible for CIP4 
dimerization and interaction with membrane phospholi ids; cdc42 interacting domain (HR1, 
CIP4 395-475) and SH3 domain (CIP4 544-598). (B) In vitro phosphorylation. (His)6-tagged 
CIP4, CIP4(T225A) and CIP4(S296A/S421A/S426A) attached to Ni beads were incubated with 
the catalytic subunit of PKA as described [16]. The reactions were terminated by heating the 
samples in sample buffer at 65°C for 20 min and analyzed by western blot using a rabbit anti-
RXXS/T(Pi) antibody as in Fig. 1. (C) 3-dimensional structure of the F-BAR domain crystal 
resolved by x-ray diffraction (https://www.ncbi.nlm.nih.gov/Structure/pdb/2EFK). The T225 
residue localizes at the fourth α-helix in the convex side of the dimer. (D) Comparison of the 
CIP4 T225 sequence region in different species and in Homo sapiens CIP4-like proteins.  (E) 
MDA-MB31 cells expressing CIP4WT-GFP and CIP4T225A-GFP proteins were exposed to 10 
















immunoprecipitates were obtained by using a mouse anti-GFP antibody and phosphorylation by 
PKA in the immunoprecipitates was analyzed by western blot as in Fig. 2A. 
Fig. 3. Expression of  CIP4(T225E) increases, whereas CIP4(T225A) inhibits, HepG2 migratory 
properties. (A) Equal amounts of control cells (not expressing GFP) and CIP4 WT, 
CIP4(T225A) or CIP4(T225E) cells were mixed and seeded to confluence to perform wound 
healing assays. Cells were fixed at 24 h and stained with DAPI for confocal microscopy. The 
amount of cells not expressing GFP (control) and cells expressing CIP4 fusion proteins at the 
wound edge (WE) and in the unperturbed confluent monolayer (ML) were determined. The 
images show cell distribution at the wound edge for each group. (B) Bars represent the average 
ratio between the percentages of cells in both locati ns for each group of cells. Data are 
expressed as means±s.e.m. for at least 150 cells distributed in six separate fields for each 
location, representative of four independent experim nts. *p<0.05 compared to its control. (C) 
Cells were fixed 6 h after scratch wounding and stained using an anti-γ tubulin antibody and 
DAPI for centrosome and nucleus visualization, respectively. Images were obtained by confocal 
microscopy and analyzed using ImageJ software. The difference between the distance from the 
centroid of the centrosome or the nucleus and the distance from the cell centroid to the line 
tangent to the leading edge was calculated and divied by the distance from the cell centroid to 
the leading edge. Negative values refer to organelle localization behind the cell centroid, whereas 
positive values indicate organelle localization in front of the cell centroid. Bar graph illustrates 
the position of the nucleus (gray) or the centrosome (black) in cells at the wound edge. Data are 
expressed as mean±s.e.m. of at least 40 cells, repres ntative of three independent 
experiments.*p<0.05 compared to nucleus, #p<0.05 compared to control. (D) Western blot 
analysis of E-cadherin expression in control, CIP4 WT, CIP4(T225A) and CIP4(T225E) cells. 
Cell lysates were prepared and analyzed by western blot using mouse monoclonal anti-E-
cadherin (BD Bioscience-610182, 1:1000) and monoclonal anti-alpha tubulin (Sigma-T9026, 
















relative to the loading control of three independent experiments. (E) Wound healing assays were 
performed as in A, in the absence or presence of the PKA inhibitor, H89 (1 µM), and quantified 
as in B. Data are expressed as mean±s.e.m. of at least 150 cells distributed in six separate fields 
corresponding to each location, representative of three independent experiments. *p<0.05 
compared to control. Scale bars: 10 µm. 
Fig. 4. Phosphorylation at CIP4 T225 modulates HepG2 invasive capacity in vitro and metastasis 
in vivo. (A) Invasion assays in Boyden chambers. Invasion capacity was assessed for the 
different cell lines using Matrigel-coated transwells. Cells were seeded into the upper chamber 
and incubated for 48 h. Cells in the upper chamber were removed and the remaining cells were 
fixed and stained for optical microscopy. Bars represent the ratio of cells that invaded into the 
lower chamber for each cell line related to control cel s, quantified in ten different fields for three 
independent experiments. *p<0.05 compared to control. #p<0.05 compared to CIP4 WT. (B-D) 
Experimental metastasis assay. Control HepG2, CIP4 WT, CIP4(T225A) or CIP4(T225E) cell 
lines were injected via the tail vein into athymic nude mice. After 8 weeks, animals were 
sacrificed and the lungs were fixed and stained with ink to visualize metastatic nodules by 
counterstaining and direct fluorescence. (B) Bars represent the number of metastases observed 
per lung for each group. *p<0.05 compared to control. #p<0.05 compared to CIP4 WT. (C) The 
table shows the number of mice that developed lung metastases after  tail vein injection of the 
indicated HepG2 cells. The x/y ratio indicates the number of animals that scored positive 
metastases in lung (x) versus the total number of mice analyzed in the experiments (y). (D) 
Representative images of hematoxylin and eosin staiing of lung tissue from athymic nude mice 
injected with the different cell lines showing metastatic foci of cancer cells (black circles). Scale 
bars: 50 µm (A), 100 µm (D). 
Fig. 5. Expression of CIP4(T225E) increases, whereas CIP4(T225A) represses, MDA-MB-231 
migratory and invasive properties. (A) Wound healing assays performed in MDA-MB231 cells 
















experiment,  the intact monolayer was scratched, an cells were allowed to migrate for 6 h. 
Images of the same field acquired at 0 and 6 h wereanalyzed using the ImageJ software. Bars 
represent the average distance migrated in µm by each cell line. *p<0.01 compared to control. 
(B) Representative images of invasion assays in Boyden chambers. Cell invasiveness was 
studied using Matrigel coated transwells. Cells were seeded into the upper chamber and 
incubated with or without PKI. After 24 h, cells in the upper chamber were removed and the 
remaining cells were fixed and stained with toluidine blue for optical microscopy. Bars represent 
the ratio of cells that invaded the lower chamber related to control cells. *p<0.01 compared to 
control PKI (-). &p<0.01 compared to control PKI (+). #p<0.01 PKI (-) compared to PKI (+) 
within the same group. Data are expressed as mean±s.e.m. of at least eight (A) or ten (B) fields, 
representative of three independent experiments. Scale bars: 50 µm (A,B). 
Fig. 6. Expression of the CIP4(T225E) phosphomimetic mutant promotes spontaneous 
metastasis in MDA-MB-231 orthotopic xenografts.  Fifty µl of a suspension containing 1 x 106 
MDA-MB-231 cells in a 50:50 solution of Matrigel/PBS was introduced into the right inguinal 
mammary gland of anaesthetized, 6-week-old female athymic nude mice. (A) Primary tumor 
growth was estimated by measuring tumor length (a) and width (b) every 3-4 days, and tumor 
volume (V) was calculated using the formula V = 0.4ab2. (B) After 12 weeks, mice were 
euthanized, the chest cavity was exposed through a midline chest incision and the presence of the 
primary tumors was corroborated by direct visualization. (C) The trachea was cannulated, and 
lungs inflated using 1 ml of Indian ink. Lungs were th n extracted and destained, and metastatic 
nodules counted e visu. The x/y ratio indicates the number of mice that scored positive for 
metastasis (x) versus the total number analyzed in the experiments (y) for the different groups of 
mice. (D) Bars represent the number of metastases formed in the lungs per mouse by each 
indicated MDA-MB-231 cell line. (E) Representative images of hematoxylin and eosin staining 
of lung tissue from athymic nude mice injected with the indicated cells showing metastatic foci 
















Fig. 7. CIP4 T225 phosphorylation affects the formation of functional invadopodia and CIP4 
interaction with CDC42. (A) Cells were incubated on coverslips coated with gelatin conjugated 
to FITC for 16 h at 37ºC and then fixed and stained with phalloidin-Alexa 555 and anti-cortactin-
antibody. Foci of degraded matrix were visible as drk areas of 0.2 to 1.2 µm in diameter in the 
bright fluorescent gelatin matrix (arrows). Images show DAPI (blue), actin (red) and cortactin 
(green) staining and FITC-gelatin (cyan). x,z Orthogonal views are shown below each x,y 
merged image. (B) A cell generating at least one “hole” under the cell or near the cell edge was 
counted as a cell able to degrade matrix (invasive cell). Bars represent the number of invasive 
cells, expressed as percentage of total cells for each cell line. *p<0.05 compared to CIP4 WT and 
CIP4(T225E). (C) Functional invadopodia were identified as actin- and cortactin-rich structures 
localized close to foci of degraded matrix. Bars represent the total number of invadopodia per 
invasive cell for each cell line. *p<0.05 compared to CIP4 WT and CIP4(T225E). (D) Cells were 
seeded on matrigel coated coverslips, incubated for 16 h and then fixed and stained with 
phalloidin for confocal microscopy. Invadopodia were identified as actin dots, positive for CIP4-
GFP fluorescence, in contact with the ECM. Merged images show the visualization of CIP4 
(green) and actin (red) staining in MDA-MB 231 cells expressing CIP4 WT, CIP4(T225A) or 
CIP4(T225E). White arrowheads indicate representative invadopodia. The panels below each  
x,y image show the x,z magnified views of a representative invadopodia. Brs represent average 
GFP intensities measured at invadopodia (Av Finv) related to the average GFP intensity in the 
cell (Av Fcell) for each construct. Data are expressed as mean±s.e.m. of at least thirty cells, 
representative of three independent experiments. *p<0.05 compared to CIP4 WT. (E) Confocal 
images of MDA-MB 231 cells expressing CIP4-GFP fusion constructs and stained for CDC42 
using a secondary antibody bound to Alexa 555. Delimited areas represent the photobleached 
regions. Briefly, a region of interest (ROI) which included the cell edge was photobleached at 
555 nm wavelength and images were taken before and after photobleaching. Total GFP 
















efficiency as described in the materials and methods. FRET efficiency was also calculated for 
MDA-MB 231 cells expressing GFP and stained for CDC42, and for each image outside the 
photobleached ROI (no ROI) (negative controls). FRET images show the difference in GFP 
fluorescence after and before acceptor photobleaching, represented in pseudocolor.  Bars 
represent the FRET efficiency calculated for each cell line. Data are expressed as mean±s.e.m. of 
ten photobleached areas, representative of three ind pendent experiments.*p<0.05 compared to 
CIP4WT (ROI). #p<0.01 compared ROI vs. no ROI in the same group. Scale bars: 5 µm (A, E) 














AKAP350 enables CIP4 phosphorylation by PKA, which occurs at the CIP4 T225 residue. 
CIP4 T225 is a relevant substrate in PKA regulation of breast cancer cell invasiveness. 
CIP4 T225 phosphorylation regulates CIP4/CDC42 interaction and invadopodia formation. 
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